EA202190134A1 - Соединения аминокислот с неразветвленными линкерами и способы их применения - Google Patents

Соединения аминокислот с неразветвленными линкерами и способы их применения

Info

Publication number
EA202190134A1
EA202190134A1 EA202190134A EA202190134A EA202190134A1 EA 202190134 A1 EA202190134 A1 EA 202190134A1 EA 202190134 A EA202190134 A EA 202190134A EA 202190134 A EA202190134 A EA 202190134A EA 202190134 A1 EA202190134 A1 EA 202190134A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
unbranged
linkers
methods
application
Prior art date
Application number
EA202190134A
Other languages
English (en)
Inventor
Катерина Лефтерис
Морин Рейлли
Даррен Финкельштайн
Николь Купер
Кристофер Бейли
Якоб Ча
Original Assignee
Плайэнт Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Плайэнт Терапьютикс, Инк. filed Critical Плайэнт Терапьютикс, Инк.
Publication of EA202190134A1 publication Critical patent/EA202190134A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Devices That Are Associated With Refrigeration Equipment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Изобретение относится к соединениям формулы (A)или их солям, где R1, R2, R5a, R5b, R6a, R6b, R7a, R7b, R8a, R8b, R9a, R9b, R10a, R10b, R11a, R11b, R21, n и G являются такими, как описано в данном документе. Соединения формулы (I) и их фармацевтические композиции являются ингибиторами интегрина V6, которые пригодны для лечения фиброза, такого как идиопатический фиброз легких (IPF), и неспецифической интерстициальной пневмонии (NSIP).
EA202190134A 2018-06-27 2019-06-27 Соединения аминокислот с неразветвленными линкерами и способы их применения EA202190134A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862690939P 2018-06-27 2018-06-27
PCT/US2019/039624 WO2020006315A1 (en) 2018-06-27 2019-06-27 Amino acid compounds with unbranched linkers and methods of use

Publications (1)

Publication Number Publication Date
EA202190134A1 true EA202190134A1 (ru) 2021-03-26

Family

ID=68987528

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190134A EA202190134A1 (ru) 2018-06-27 2019-06-27 Соединения аминокислот с неразветвленными линкерами и способы их применения

Country Status (21)

Country Link
US (2) US11396506B2 (ru)
EP (1) EP3813818A4 (ru)
JP (2) JP7425757B2 (ru)
KR (1) KR20210043561A (ru)
CN (1) CN112689507A (ru)
AU (1) AU2019295769B2 (ru)
BR (1) BR112020026278A2 (ru)
CA (1) CA3104682A1 (ru)
CL (1) CL2020003382A1 (ru)
CR (1) CR20210041A (ru)
CU (1) CU24693B1 (ru)
DO (1) DOP2020000255A (ru)
EA (1) EA202190134A1 (ru)
EC (1) ECSP21005655A (ru)
IL (2) IL308960A (ru)
JO (1) JOP20200330A1 (ru)
MX (1) MX2020014086A (ru)
PE (1) PE20210137A1 (ru)
PH (1) PH12020552260A1 (ru)
SG (1) SG11202013027RA (ru)
WO (1) WO2020006315A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
JP2020504120A (ja) 2016-12-29 2020-02-06 セントルイス ユニバーシティ インテグリンアンタゴニスト
RU2769702C2 (ru) 2017-02-28 2022-04-05 Морфик Терапьютик, Инк. Ингибиторы интегрина avb6
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CR20200452A (es) 2018-03-07 2020-11-19 Pliant Therapeutics Inc Compuestos de aminoacidos y métodos de uso
KR20210024586A (ko) 2018-06-27 2021-03-05 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물
BR112020026278A2 (pt) 2018-06-27 2021-04-06 Pliant Therapeutics, Inc. Compostos de aminoácidos com ligantes não ramificados e métodos de uso
EP4086254A1 (en) 2018-08-29 2022-11-09 Morphic Therapeutic, Inc. Integrin inhibitors
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
AU2020273158A1 (en) 2019-04-08 2021-11-11 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds
US20230055657A1 (en) * 2019-12-20 2023-02-23 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
CA3164941A1 (en) * 2019-12-20 2021-06-24 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
GB202209228D0 (en) 2022-06-23 2022-08-10 Univ Strathclyde Modified amino acids and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69829996T2 (de) * 1997-12-17 2006-02-23 Merck & Co., Inc. (A New Jersey Corp.) Integrin-rezeptor-antagonisten
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6329372B1 (en) * 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
JP2009539815A (ja) * 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
WO2008093064A1 (en) * 2007-01-29 2008-08-07 Astrazeneca Ab L-ALANINE DERIVATIVES AS α5 BETA 1 ANTAGONISTS
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
CN104817604B (zh) 2015-03-16 2017-08-04 邦泰生物工程(深圳)有限公司 一种β‑烟酰胺单核苷酸的纯化方法
JP2018514568A (ja) * 2015-04-30 2018-06-07 サイフルーア ライフ サイエンシズ インコーポレイテッド テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法
WO2018009501A1 (en) 2016-07-05 2018-01-11 The Rockefeller University Tetrahydronaphthyridinepentanamide integrin antagonists
CN109996541A (zh) * 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
MA46744A (fr) * 2016-11-08 2019-09-18 Bristol Myers Squibb Co Composés mono et spirocycliques contenant du cyclobutane et de l'azétidine en tant qu'inhibiteurs de l'intégrine alpha v
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
RU2769702C2 (ru) 2017-02-28 2022-04-05 Морфик Терапьютик, Инк. Ингибиторы интегрина avb6
EP3760202A1 (en) * 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CR20200452A (es) 2018-03-07 2020-11-19 Pliant Therapeutics Inc Compuestos de aminoacidos y métodos de uso
BR112020026278A2 (pt) 2018-06-27 2021-04-06 Pliant Therapeutics, Inc. Compostos de aminoácidos com ligantes não ramificados e métodos de uso
EP4086254A1 (en) 2018-08-29 2022-11-09 Morphic Therapeutic, Inc. Integrin inhibitors
WO2020047207A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
AU2020273158A1 (en) 2019-04-08 2021-11-11 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds
US20210147526A1 (en) 2019-11-15 2021-05-20 Pliant Therapeutics, Inc. Compositions and methods for activation of integrins
KR20230049584A (ko) 2020-05-07 2023-04-13 플라이언트 테라퓨틱스, 인크. 아미노산 화합물을 사용한 호흡기 질환의 치료
CA3173755A1 (en) 2020-11-19 2022-05-27 Pliant Therapeutics, Inc. Integrin inhibitor and uses thereof
JP2024517765A (ja) 2021-04-30 2024-04-23 プライアント・セラピューティクス・インコーポレイテッド インテグリン阻害剤の拡大投与レジメン
WO2023035000A1 (en) 2021-09-03 2023-03-09 Pliant Therapeutics, Inc. Therapeutic modulation of integrins
CA3234791A1 (en) 2021-10-14 2023-04-20 Eric Lefebvre Integrin inhibitors and uses thereof in combination with other agents

Also Published As

Publication number Publication date
JP2024055873A (ja) 2024-04-18
ECSP21005655A (es) 2021-02-26
BR112020026278A2 (pt) 2021-04-06
IL308960A (en) 2024-01-01
JP2021529755A (ja) 2021-11-04
PH12020552260A1 (en) 2021-08-16
AU2019295769B2 (en) 2024-05-23
JP7425757B2 (ja) 2024-01-31
CU20210001U (es) 2023-01-16
KR20210043561A (ko) 2021-04-21
AU2019295769A1 (en) 2021-02-11
PE20210137A1 (es) 2021-01-21
CU20210001A7 (es) 2021-08-06
EP3813818A4 (en) 2023-01-11
TW202010492A (zh) 2020-03-16
JOP20200330A1 (ar) 2020-12-20
CN112689507A (zh) 2021-04-20
SG11202013027RA (en) 2021-01-28
US11396506B2 (en) 2022-07-26
CR20210041A (es) 2021-03-02
IL279717B1 (en) 2024-01-01
CA3104682A1 (en) 2020-01-02
DOP2020000255A (es) 2021-05-16
US20220289743A1 (en) 2022-09-15
EP3813818A1 (en) 2021-05-05
MX2020014086A (es) 2021-04-13
US20200123151A1 (en) 2020-04-23
WO2020006315A1 (en) 2020-01-02
US11858931B2 (en) 2024-01-02
CL2020003382A1 (es) 2021-05-14
IL279717A (en) 2021-03-01
IL279717B2 (en) 2024-05-01
CU24693B1 (es) 2024-02-07

Similar Documents

Publication Publication Date Title
EA202190134A1 (ru) Соединения аминокислот с неразветвленными линкерами и способы их применения
CR20200452A (es) Compuestos de aminoacidos y métodos de uso
EA202190967A1 (ru) Аминокислотные соединения и способы применения
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
MX2018005204A (es) Inhibidores de isoindolina, azaisoindolina, dihidroindenona y dihidroazaindenona de cinasas 1 y 2 de interaccion con proteina cinasas activadas por mitogenos (mnk1 y mnk2).
CY1117728T1 (el) Στερεες μορφες 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλ) κυκλοπροπανοκαρβοξαμιδο)-3-μεθυλπυριδιν-2-υλ)βενζοϊκου οξεος
CY1119489T1 (el) Υποκατεστημενη πιπεριδυλο-αιθυλο-πυριμιδινη ως αναστολεας της ο-ακυλο τρανσφερασης της γκρελινης
CY1118774T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης
MX2018005203A (es) Compuestos de pirrolo-, pirazolo-, imidazo-pirimidina y pirrolo-, pirazolo-, imidazo-piridina que inhiben cinasas 1 y 2 de interaccion con proteina cinasas activadas por mitogenos (mnk1 y mnk2).
PH12017501397B1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
PH12017501444A1 (en) (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
EP4249072A3 (en) Crystalline forms of quinolone analogs and their salts
EA202092190A1 (ru) Композиции и способы для лечения сильного запора
SG11202006943TA (en) Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide
PE20221630A1 (es) Derivado de amino arilo novedoso util como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo
EA202092110A1 (ru) Аминокислотные соединения и способы применения
TH2101001964A (th) สารประกอบอินโดลิโนนสำหรับใช้เป็นสารยับยั้งmap4k1